Profile: Pfizer Inc (PFE)
17 Feb 2017
Pfizer Inc. (Pfizer), incorporated on June 2, 1942, is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. The Company's segments include Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). Its portfolio includes medicines, vaccines and medical devices, as well as consumer healthcare products. Its biopharmaceutical products include Lipitor, Sutent and the Premarin family of products. Its biotechnology products include BeneFIX, ReFacto and Xyntha.
The Company's contract manufacturing business, Pfizer CentreOne, consists of its contract manufacturing and active pharmaceutical ingredient sales operation, including manufacturing and supply agreements with Zoetis Inc., and Hospira’s One-2-One sterile injectables contract manufacturing operation. Its research focuses on six areas, which include immunology and inflammation, cardiovascular and metabolic diseases, oncology, vaccines, neuroscience and pain, and rare diseases. In addition, it focuses on biosimilars. The Company has collaboration and/or co-promotion agreements relating to certain biopharmaceutical products, including Enbrel (in the United States and Canada), Spiriva and Rebif. The Company's subsidiaries include Hospira, Inc. and Medivation, Inc.
Pfizer Innovative Health
The Company's IH segment focuses on developing and commercializing medicines and vaccines that improve patients’ lives, as well as products for consumer healthcare. Its therapeutic areas include vaccines, oncology, inflammation/immunology, cardiovascular/metabolic, neuroscience/pain, rare diseases and consumer healthcare, and include brands, such as Prevnar/Prevenar 13, Xeljanz, Eliquis, Lyrica (the United States, Japan and certain other markets), Enbrel (outside the United States and Canada) and Viagra (the United States and Canada), as well as several over-the-counter (OTC) consumer products. Its oncology products include Sutent, Ibrance, Xalkori and Inlyta.
The Company's Consumer Healthcare business products are categorized into Dietary Supplements, Pain Management, Gastrointestinal, and Respiratory and Personal Care. The Company's Dietary Supplements products include Centrum brands, including Centrum, Centrum Silver, Centrum Men's and Women's, Centrum VitaMints, Centrum Specialist, Centrum Flavor Burst and Centrum Kids; Caltrate, and Emergen-C. Its Pain Management products include Advil brands, including Advil, Advil PM, Advil Liqui-Gels, Advil Film Coated, Children's Advil, Infants' Advil and Advil Migraine, and ThermaCare. Its Gastrointestinal products include Nexium 24HR/Nexium Control and Preparation H. The Company's Respiratory and Personal Care include Robitussin, Advil Cold & Sinus, Advil Sinus Congestion Relief & Pain, Dimetapp and ChapStick.
Pfizer Essential Health
The Company's EH segment includes legacy brands that have lost or will soon lose market exclusivity in both developed and emerging markets, branded generics, generic sterile injectable products, biosimilars and infusion systems. EH segment also includes a new EH research and development organization, as well as contract manufacturing business.
The product categories in EH segment include Legacy Established Products, Peri-LOE Products, Sterile Injectable Pharmaceuticals, Infusion Systems, Biosimilars and Other Established Products. Its Legacy Established Products includes products that have lost patent protection. Its Peri-LOE Products includes products that have lost or are anticipated to soon lose patent protection. These products primarily include Celebrex, Zyvox and Revatio in most developed markets, Lyrica in the EU, Pristiq in the United States and Inspra in the European Union. The Company's Sterile Injectable Pharmaceuticals includes generic injectables and specialty injectables. The Company's Infusion Systems includes medication management systems products composed of infusion pumps and related software and services, as well as intravenous therapy (I.V.) infusion products, including I.V. solutions and their associated administration sets. The Company's Biosimilars includes Inflectra (biosimilar infliximab) in Canada, Mexico, Australia and certain European markets, Nivestim (biosimilar filgrastim) in Australia and certain European and Asian markets and Retacrit (biosimilar epoetin) in certain European markets. The Company's Other Established Products includes Hospira's One-to-One contract manufacturing and bulk pharmaceutical chemical sales organizations.
235 E 42ND ST
NEW YORK NY 10017-5703
Company Web Links
- Roche says Phase II trial supports twin treatment for kidney cancer
- BRIEF-Momenta Pharmaceuticals announces FDA warning letter to contracted Glatopa
- BlackRock's largest mutual fund sours on Google
- BRIEF-Pfizer says new data in Crohn's disease patients shows similar efficacy and safety profiles for Inflectra and Remicade A
- BRIEF-Pfizer announces top-line results from oral strategy trial of Xeljanz compared to Humira